Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending December 6, 2020 Durable responses with anti-BCMA CAR T-cell for multiple myeloma, Allogeneic transplant leads to durable remissions in T-cell lymphomas, ZUMA-5: Axi-cel yields high response rate in indolent NHL, COVID-19–related outcomes poor for patients with hematologic disease in ASH registry, Fear of recurrence highly prevalent in RCC survivors, More must reads Must reads for theWeek ending November 29, 2020 Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest, Reduced cancer mortality with Medicaid expansion, Neoadjuvant immunotherapy combo produces high response rate in melanoma, Circulating miRNA could be a potential biomarker for early diagnosis of MM, Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia, More must readsMust reads for theWeek ending November 22, 2020 Immunotherapy could fill unmet need in leptomeningeal metastases, Vaccine regimen boosts immune response in malignant melanoma, HCC rates slow in cities, continue to climb in rural areas, Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction, Risk factors for severe immune-related AEs identified, More must readsMust reads for theWeek ending November 15, 2020 Lung cancer: Proton beam radiotherapy likely reduces cardiovascular events, New cancer drugs may have saved more than 1.2 million Americans, Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients, Beat AML: Precision medicine strategy feasible, superior to SOC for AML, Study supports genetic testing in older women with breast cancer, More must readsMust reads for theWeek ending November 8, 2020 Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC, COVID-19 in pregnancy raises risk of preterm birth and severe disease, New case suggestive of in utero SARS-CoV-2 transmission, Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC, Family planning issues loom large for female radiation oncologists, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 last »
